J&J's Stelara Gets Europe OK For Pediatric Psoriasis
Healthcare Giant's Best-Selling Drug
The European Commission has backed J&J's blockbuster to treat children with psoriasis but the drug has fallen foul of NICE for ulcerative colitis.
You may also be interested in...
A strong fourth quarter and full-year 2019 performance by J&J was driven by significant sales growth for Tremfya and Stelara. CFO Wolk said a $4bn opioids settlement remains on track.
Novartis’s cancer drug has now been filed for multiple sclerosis in the US, armed with a priority review, and in Europe.